Hema Now | Episode 4
This week Jonathan is joined by Joshua Zeidner, Associate Professor of Medicine, University of North Carolina School of Medicine, USA. Together, they discuss findings from recent research and treatment options for acute myeloid leukaemia and myelodysplastic syndrome.
Spotify | Apple | Amazon Music | Download MP3 (35 mins)
Joshua Zeidner is an Associate Professor of Medicine at the University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, where he is the Section Chief of Leukaemia Research, Associate Chief of Research within the Division of Hematology, and the inaugural Director of Clinical Cancer Research, Commercial Integration, at Lineberger Comprehensive Cancer Center.
Zeidner’s research focuses on drug development, early phase clinical trials, and innovative therapeutic strategies in acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) with a particular interest in immunotherapeutic approaches, and therapies targeted towards differentiation and apoptotic pathways. He has designed and developed multiple Phase I-II studies in AML and oversees a robust clinical research program in Leukaemia at University of North Carolina.
Outside of Medicine, Zeidner is an avid sports fan and in particular is passionate about New York Giants Football and University of North Carolina Basketball and Football. He enjoys spending time with his family, the beach, traveling, music, and cooking.
- 00:00 – Introduction
- 01:57 – Joshua’s love for the New York Giants
- 04:28 – Treatment outcomes in IDH1 and IDH2-mutated acute myeloid leukaemia (AML)
- 08:05 – Safety and efficacy of new agents in AML
- 17:00 – Treatments for patients with AML with a TP53 mutation
- 22:02 – Reliance on transfusion in myelodysplastic syndrome (MDS)
- 25:44 – The time from research lab to bedside in drugs to treat AML and MDS
- 30:50 – Joshua’s three wishes for healthcare
- 35:13 – Outro
